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Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been 
confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase in-
hibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were 
associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients 
treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide 
repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 
and single nucleotide polymorphisms (SNP-216) in the promoter region of the 
EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length 
polymorphism and DNA sequencing. The relationship between genetic polymor-
phisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Re-
sults: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-
TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G 
(62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with 
longer progression-free survival compared with the GG genotype (16.7 months vs. 
5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with 
the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a po-
tential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.
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INTRODUCTION
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs), such as erlotinib and gefitinib, were initially developed for use as a second-
line therapy after failure of cytotoxic chemotherapy regimens.1,2 In this setting, erlo-
tinib was shown to increase survival, with the magnitude of benefit similar to that of 
second-line chemotherapy.1 Both clinical and molecular parameters are helpful in 
predicting which patients with advanced non-small cell lung cancer (NSCLC) are 
most likely to benefit from treatment with EGFR-TKIs. The clinical parameters as-
sociated with response to EGFR-TKI therapy include adenocarcinoma, female sex, 
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or erlotinib after receiving prior chemotherapy treatment at 
Yonsei Cancer Center, Yonsei University College of Medi-
cine, Seoul, Korea, from January 2007 to December 2010. 
The variables used in the pretreatment analysis were age, 
sex, clinical stage, ECOG PS, histological type, smoking 
history, number of prior chemotherapy regimens, and if 
possible, EGFR mutation status. Histological analysis of tu-
mors was based on the WHO classification for cell types.18 
Patients received a daily dose of 150 mg of erlotinib or 250 
mg of gefitinib. Erlotinib or gefitinib was continued until 
disease progression, intolerable toxicity, or patient refusal. 
Patients were evaluated every eight weeks by computed to-
mography and clinical responses were defined according to 
the RECIST 1.1 response evaluation criteria for patients 
with measurable disease.19
EGFR mutation detection and genotyping 
EGFR mutation detection methodologies have been pub-
lished elsewhere, and we sequenced exons 18-21 of the TK 
domain of EGFR in tumors.20 For detection of EGFR poly-
morphisms, genomic DNA was purified from leukocytes af-
ter selective lysis of erythrocytes using an automated DNA 
extractor, according to the manufacturer’s instructions (Ap-
plied Biosystems, Foster City, CA, USA). Genotyping of the 
promoter region of EGFR-216 was performed using poly-
merase chain reaction (PCR), and polymorphism assignment 
was determined by restriction enzyme digestion using previ-
ously described methods.17 CA-SSR1 was amplified by PCR 
and sequenced using a previously reported method.15 
 
Statistical methods
The association between the presence of CA-SSR1 or SNP-
216 and other categorical clinical variables was assessed 
using the χ2 test or Fisher’s exact test. Progression-free sur-
vival (PFS) was defined as the time from the start date of 
TKI treatment until the date of tumor progression or death. 
Overall survival (OS) was measured from the start date of 
TKI therapy to the date of death or final follow-up. Survival 
was estimated using a Kaplan-Meier curve and compared 
using the log-rank test. A p-value of less than 0.05 was con-
sidered statistically significant.
 
RESULTS
 
Patient characteristics 
The demographic characteristics of the 71 subjects are 
non-smokers and Asian ethnicity.3-5 In addition, specific acti-
vating mutations in the TK domain of the EGFR are associ-
ated with increased responsiveness to EGFR-TKIs.6-9
However, a previous study found that gefitinib was not 
effective in EGFR mutation-negative patients, although the 
patients were expected to demonstrate a good response to 
treatment with EGFR TKIs, as all patients had adenocarci-
noma, were Asian, and were either never smokers or for-
mer light smokers.10,11 Therefore, the most exact predictive 
marker of EGFR-TKIs may be EGFR mutation. Unfortu-
nately, the detection of an EGFR mutation is difficult due to 
a limited amount of available tissue.12 Thus, another bio-
marker that can improve the prediction of response to these 
targeted drugs is needed. 
Recently, EGFR amplification has been identified as a 
predictive marker for response to EGFR-TKI therapy.13,14 
The polymorphisms of the gene may regulate protein ex-
pression. The CA simple sequence repeat in intron 1 (CA-
SSR1) is a highly polymorphic dinucleotide CA repeat in 
intron 1 of the EGFR gene that is related to transcriptional 
activity and may predict the outcome of EGFR-TKI thera-
py in NSCLC patients.15,16 In addition, single nucleotide 
polymorphisms (SNPs) in the promoter region of the 
EGFR gene may correlate with increased promoter activity 
and EGFR expression. One such SNP, SNP-216, is located 
216 base pairs upstream from the initiator ATG and exerts a 
strong influence on EGFR transcription in vivo.17
Therefore, the length of CA-SSR1 and the genotype of 
SNP-216 may affect EGFR expression and function, which 
may determine outcomes of EGFR-TKI treatment. In addition, 
polymorphisms are consistent features that can easily be as-
sessed from blood cells, therefore making them useful mark-
ers, especially when the patients do not have available tissue. 
Moreover, there are allele frequency differences between eth-
nic groups, which may contribute to different drug responses. 
Thus, we investigated whether these two genotypes of EGFR 
can serve as predictive markers for clinical outcomes in Kore-
an NSCLC patients treated with EGFR-TKIs.
MATERIALS AND METHODS
　　　
Eligible patients and treatment
In this study, 71 patients with advanced NSCLC were en-
rolled. Eligible patients had at least one measurable lesion, 
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 0-2, and each patient received gefitinib 
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tation status was analyzed in 44 of 71 patients (62%), and 
21 of the 44 patients (44.7%) were positive. Overall, 37 pa-
tients (52.1%) were treated with gefitinib. 
Genotyping of EGFR
In 142 chromosomes, the median number of CA repeats was 
20 (range, 15-24) (Table 2). The most frequent CA-SSR1 
genotype was 20/20 repeats found in 18 patients (25.3%); al-
lele 16/16 was found in only two patients (2.8%). The medi-
an of the sum of CA repeat numbers in both alleles was 37 
(range, 31-44), and we classified patients as “longer” for 
those with greater than 37 repeats and as “shorter” for those 
with 37 repeats or fewer, according to the median of the sum 
of repeat numbers in both alleles based on a previous study.15 
For SNP-216 polymorphism, 63 patients (88.7%) exhibited 
the GG genotype; GT was present in only 8 patients (11.3%); 
and TT was present in none.
There were no differences in clinical characteristics ac-
cording to CA-SSR1 and SNP-216 genotypes (data not 
shown). EGFR mutation positivity was not associated with 
CA repeats and SNP-216. However, seven of eight patients 
who had the GT genotype of SNP-216 exhibited a shorter 
CA-SSR1 (Table 3). 
Genotypes and response to EGFR-TKI therapy
Responses were evaluated in all 71 patients. A partial re-
sponse was noted in 23 patients, generating an RR of 32.4%, 
and an additional 27 patients (37.6%) demonstrated the best 
response of stable disease. No significant association was 
found between response and the length of CA repeats. Also, 
there was no difference in the relationship between SNP-
216 or CA-SSRI polymorphism and the efficacy of EGFR-
TKIs according to EGFR mutation status (Supplementary 
Table 1). Patients with the GT genotype of SNP-216 tend to 
show higher response rates than patients with the GG geno-
type (62.5% vs. 27%, p=0.057). In addition, patients with 
the GT genotype had a higher disease control rate than those 
with GG (87.5% vs. 66.7%, p=0.042). Better responses 
were also achieved in those that never smoked, had re-
ceived TKI therapy as a second line therapy, were positive 
for the EGFR mutation, and were female (Table 4).
shown in Table 1. The median age of the patients was 59 
years (range, 34-85). Females and never smokers account-
ed for 38% and 42.3% of patients, respectively. EGFR mu-
Table 1. Patient Baseline Characteristics
All patients (n=71)
n %
Age 
    Median (range) 59 (34-85)
    ≤65 49 70
    >65 22 30
Gender
    Female 27 38
    Male 44 62
Performance status
    0-1 66   78.9
    2 15   21.1
Smoking
    Never 30   42.3
    Ever 41   57.7
No. of prior regimens
    ≤1 25   35.2
    ≥2 46   64.8
TKI
    Gefitinib 37   52.1
    Erlotinib 34   47.9
EGFR mutation 
    Negative 23   32.4
    Positive 21   29.6
    Unknown 27   38.0
TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor.
Table 2. Allele Distribution of CA-SSR1 Repeat Length
Allele Frequency Percent
15 10     7.0 
16 27   19.0 
17   5     3.5 
18   2     1.4 
19 12     8.5 
20 77   54.2 
21   5     3.5 
22   2     1.4 
23   1     0.7 
24   1     0.7 
Total 142 100.0 
CA-SSR1, CA simple sequence repeat in intron 1.
Table 3. The Relationship between SNP-216 and Repeat Length of CA-SSR1 or EGFR Mutation
CA-SSR1 (%)
p value
EGFR mutation
p value
Shorter Longer Positive Negative Unknown
SNP-216
GG 27 (42.9) 36 (57.1) 0.024 19 (30.2) 20 (31.7) 24 (38.1) 0.934
GT   7 (87.5)   1 (12.5)   2 (25.0)   3 (37.5)   3 (37.5)
SNP, single nucleotide polymorphism; CA-SSR1, CA simple sequence repeat in intron 1; EGFR, epidermal growth factor receptor.
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all survival than those with poor performance status, and 
there was no difference in overall survival according to oth-
er clinical characteristics and genotypes (Fig. 2).  
DISCUSSION
We hypothesized that genetic polymorphisms of EGFR might 
be associated with the efficacy of EGFR-TKI treatment in 
advanced NSCLC. We found that the incidence of patients 
with the G/T genotype of SNP-216, a minor form of the 
SNP, was very low (11.8%), and these patients had a better 
response to and longer survival after EGFR-TKI therapy. 
However, the CA-SSR1 was longer than that seen in a 
Western population15 and was not associated with response 
to EGFR-TKI.
Genotypes and survival for EGFR-TKI therapy
The median follow-up duration for all 71 patients was 12.7 
months (range, 1.1-60.8 months). The median PFS was 6.0 
months (95% CI, 3.5-8.5 months), and the median OS was 
29.6 months (95% CI, 17.4-41.7 months). Patients with the 
GT genotype of SNP-216 had significantly longer PFS than 
those with the GG genotype (16.6 months vs. 5.1 months, 
p=0.047). In addition, the patients with an EGFR mutation 
reported longer survival than those without (8.3 months vs. 
2.7 months, p=0.017). Notably, among the patients for whom 
EGFR mutation status was unknown, the patients with SNP-
216G/T exhibited a longer survival than those with SNP-
216-G/G (median PFS 17.7 months vs. 5.3 months, p= 
0.068). However, there was no difference in PFS according 
to the lengths of the CA repeat (Table 5) (Fig. 1). The pa-
tients with good performance status exhibited longer over-
Table 4. Correlation of Baseline Characteristics and Genetic Polymorphism with Response to EGFR-TKIs
Number (%)
RR DCR 
n (%) p value n (%) p value
All patients   71 (100.0) 23 (32.4) 50 (70.4)
Age (yrs) 0.243 0.401
    <65 49 (69.0) 18 (36.7) 36 (73.5)
    ≥65 22 (31.0)   5 (22.7) 14 (63.6)
Sex 0.026 0.287
    Male 44 (62.0) 10 (22.7) 29 (65.9)
    Female 27 (38.0) 13 (48.1) 21 (77.8)
Performance status 0.221 0.448
    0-1 49 (69.0) 18 (36.7) 35 (71.4)
    2 22 (31.0)   5 (21.7) 15 (65.2)
Smoking history 0.028 0.947
    None 30 (42.3) 14 (46.7) 21 (70.0)
    Current+former 41 (57.7)   9 (22.0) 29 (70.7)
No. of prior regimens 0.038 0.065
    ≤1 25 (35.2) 12 (48.0) 21 (84.0)
    ≥2 46 (64.8) 11 (23.9) 29 (63.0)
TKI 0.236 0.112
    Gefitinib 37 (52.1) 11 (29.2) 23 (62.1)
    Erlotinib 34 (47.9) 12 (35.3) 27 (79.4)
SNP-216 0.057 0.042
    GG 63 (88.7) 17 (27.0) 42 (66.7)
    GT   8 (11.3)   5 (62.5)   7 (87.5)
CA-SSR1 0.875 0.15
    Short 33 (46.5) 11 (33.3) 26 (78.8)
    Long 38 (53.5) 12 (31.6) 24 (63.2)
EGFR mutation 0.013 0.106
    Negative 23 (32.4)   4 (17.4) 13 (56.5)
    Positive 21 (29.6) 12 (57.1) 18 (85.7)
    Unknown 27 (38.0)   7 (25.9) 19 (70.4)
TKI, tyrosine kinase inhibitor; SNP, single nucleotide polymorphism; CA-SSR1, CA simple sequence repeat in intron 1; EGFR, epidermal growth factor re-
ceptor; RR, response rate; DCR, disease-control rate.
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Table 5. Correlation of Baseline Characteristics and Genetic Polymorphism with Survival
Number (%)
PFS OS
Median 
(months)
95% CI p value
Median  
(months)
95% CI p value
All patients   71 (100.0) 6.0  3.5-8.5   29.6 17.4-41.7  
Age (yrs)       0.818       0.762
    <65 49 (69.0) 6.0  4.3- 7.7   24.7 10.6-38.7  
    ≥65 22 (31.0) 4.7   2.1-10.2 21.1   2.5-39.7  
Sex     0.19     0.13
    Male 44 (62.0) 5.1  3.0-7.3    21.1 10.8-31.3  
    Female 27 (38.0) 8.3  2.8-2.8    33.5 28.7-49.9  
Performance status       0.485       0.004
    0-1 49 (69.0) 6.4  2.8-8.4    33.5 14.4-52.6  
    2 23 (31.0) 5.3   1.2-16.3  13.5   7.5-19.5  
Smoking history       0.254       0.272
    None 30 (42.3) 8.3   2.6-14.0  33.5 20.8-46.2  
    Current+former 41 (57.7) 5.1 3.0-7.2    21.0 10.2-32.0  
No. of prior regimens       0.129       0.344
    ≤1 25 (35.2) 10.5   3.7-17.3  45.9 10.4-81.4  
    ≥2 46 (64.8) 4.1   1.2-70.0  23.6 15.4-31.8  
TKI       0.323       0.134
    Gefitinib 37 (52.1) 5.3 2.4-6.8    23.6 11.5-35.7  
    Erlotinib 34 (47.9) 7.5   3.8-11.2  29.5 14.7-42.5  
SNP-216       0.047       0.729
    GG 63 (88.7) 5.1 2.7-7.5    29.5 17.4-41.7
    GT   8 (11.3) 16.6   5.8-27.5    1.4   3.7-39.5
CA-SSR1       0.775       0.361
    Short 33 (46.5) 7.3   2.6-12.0  29.6 16.5-42.6  
    Long 38 (53.5) 5.3 1.2-9.4    23.6   6.8-40.3  
EGFR mutation       0.017     0.62
    Negative 23 (32.4) 2.7 0.6-4.7    18.6 16.6-36.4  
    Positive 21 (29.6) 8.3   5.3-11.3  21.1 10.9-31.2  
    Unknown 27 (38.0) 7.3   1.1-13.5  45.9 12.8-79.0  
TKI, tyrosine kinase inhibitor; SNP, single nucleotide polymorphism; CA-SSR1, CA simple sequence repeat in intron 1; EGFR, epidermal growth factor re-
ceptor; PFS, progression-free survival; OS, overall survival; CI, confidential interval.
Fig. 1. Kaplan-Meier curve of progression-free survival according to genotype. (A) SNP-216. (B) CA-SSR1 length. SNP, single nucleotide polymorphism; CA-
SSR1, CA simple sequence repeat in intron 1; PFS, progression-free survival.
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er, the minor forms, -191C/A and A/A, are extremely rare 
among Asians. Liu, et al.17 reported that no patients in an 
Asian cohort had SNP-191C/A or A/A, and Han, et al.23 re-
ported there was only one in a group of 71 NSCLC patients 
studied. Therefore, we did not analyze the sequence of the 
-191 region. 
The other SNP, 216 base pairs upstream from the initia-
tor, is in a region that encodes an important binding site for 
the transcription factor Sp1, which is necessary for activa-
tion of the EGFR gene. The incidence of SNP-216 G/T was 
low (11.3%) in the current study, and these patients tend to 
show higher responses (p=0.057) and a significantly higher 
disease control rate (p=0.042) than the others. This result 
was similar to a previous report.24 In addition, the patients 
with SNP-216 G/T showed a longer PFS (p=0.047) than 
those with the GG genotype, especially among the patients 
for whom the EGFR mutation status was unknown. This 
result suggests that the SNP-216 genotype could be used as 
The EGFR gene comprises a highly polymorphic se-
quence in intron 1 with variable numbers of the CA dinucle-
otide simple repeat, ranging from 9 to 22. Previous studies 
reported that patients with shorter CA-SSR1 demonstrated 
better responses and longer survival than those with longer 
repeats.15,16,21 However, in the current study, there was no 
difference in the efficacy of EGFR-TKI according to the 
length of CA-SSR1. The length of CA-SSR1 polymorphism 
differs by ethnicity and tends to be longer in Asians than in 
Europeans or African-Americans.22 In the current study, the 
lack of an association between the length of CA-SSR1 and 
the efficacy of EGFR-TKI therapy may be due to the small 
number of patients with shorter CA-SSR1 in our cohort.
In addition to CA-SSR1, there are two kinds of SNPs in 
the promoter region of EGFR that might be associated with 
promoter activity and mRNA expression. One of the SNPs is 
located 191 base pairs upstream from the initiator ATG and 
may be correlated with increased protein expression; howev-
Supplementary Table 1. The Relationship between SNP-216 or CA-SSR1 Polymorphism and the Efficacy of EGFR-TKIs ac-
cording to EGFR Mutation Status
SNP-216
p value*
CA-SSR1
p value
GG GT Shorter Longer
RR, n (%) EGFR mutation
Negative   3 (15.0) 1 (33.3) 0.819 
(0.712)
  2 (22.2) 2 (14.3) 0.951 
(1.000)Positive 10 (52.6)   2 (100.0)   6 (46.2) 6 (75.0)
Unknown   5 (20.8) 2 (66.7)   4 (25.0) 3 (27.3)
DCR, n (%) EGFR mutation
Negative 11 (55.0) 2 (66.7) 0.907 
(0.726)
  3 (33.3) 9 (64.3) 0.159 
(0.098)Positive 16 (84.2)   2 (100.0) 10 (76.9)   8 (100.0)
Unknown 16 (66.7)   3 (100.0) 11 (68.8) 8 (72.7)
TKI, tyrosine kinase inhibitor; SNP, single nucleotide polymorphism; CA-SSR1, CA simple sequence repeat in intron 1; EGFR, epidermal growth factor re-
ceptor; RR, response rate; DCR, disease-control rate.
*p values were obtained by comparing between EGFR mutation and SNP-216 or CA- SSR1 polymorphism using the chi-square or Fisher’s exact test (expected 
cell value <5). Data in the '( )' represent the p values by comparing the EGFR mutation negative and positive group. 
Fig. 2. Kaplan-Meier curve of overall survival according to genotype. (A) SNP-216. (B) CA-SSR1 length. SNP, single nucleotide polymorphism; CA-SSR1, CA 
simple sequence repeat in intron 1; OS, overall survival.
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a predictive marker for response to EGFR-TKI therapy, es-
pecially among patients that do not have sufficient tumor 
tissue for EGFR mutation test. However, the OS was not 
different according to SNP-216, possibly due to additional 
treatment administered after EGFR-TKI therapy. Of the 71 
total patients in the current study, 25 (35.2%) were treated 
with EGFR-TKI as a second line chemotherapy and 46 
(64.8%) received further treatment after EGFR-TKI therapy. 
In conclusion, this study showed that SNP-216 in the 
promoter region of the EGFR gene might be a predictive 
maker of EGFR TKI treatment effectiveness. Though the 
most important predictive marker for EGFR TKI effective-
ness is EGFR mutation, some patients do not have suffi-
cient tissue available for EGFR mutation test. Our findings 
are important to patients in whom EGFR mutation status is 
unknown due to lack of sufficient tumor tissue.
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